Скачать или смотреть FDA New Drug Approval May 2025: mNEXSPIKE (COVID-19 Vaccine, mRNA) Injection

May 2025 #FDA DRUG APPROVAL: mNEXSPIKE (COVID-19 Vaccine, mRNA) Injection

💊 mNEXSPIKE is a next-generation COVID-19 vaccine developed by Moderna. It is designed to provide protection against severe COVID-19 outcomes, particularly for high-risk individuals.

✅ Essential Highlights: ✅

⭕ Target Group: Recommended for individuals 65 years and older and those 12-64 years with underlying health conditions.

⭕ Dosage: Administered at one-fifth the dose of the existing Spikevax vaccine.

⭕ Approval: Approved by the U.S. FDA based on clinical trials involving 11,400 participants.

⭕ Safety & Side Effects: Common side effects include fatigue, headache, muscle pain, and fever. Severe allergic reactions & myocarditis/pericarditis have been reported in rare cases.

⭕ Availability: Expected to be available during the 2025-2026 respiratory virus season.

People can expect mNEXSPIKE to provide enhanced protection against severe COVID-19, particularly for high-risk individuals as it is having

improved efficacy and offers 9.3% higher relative vaccine efficacy compared to Moderna’s previous vaccine, Spikevax.

Become a Member of Society of Pharmaceutical Sciences and Research (SPSR) - Elevate Your Professional Journey! For more details visit https://spsrpharma.org


#SPSRWebinar #spsr #ijpsr #ijp #covid19 #coronavirus #fda #drugapproval #FDA #PharmaResearch #HolisticHealth #pharmainnovation #pharmaceuticalsciences #pharmacyprofession #stayinformed